A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
← catalyst calendarNCT06981078 · readout ≤ 438 d
Sponsored by Upstream Bio Inc. (industry) · UPB — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
666estimated
Sites
242
Countries
Argentina, Bulgaria, Chile +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-02 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Drug: Verekitug — also filed as UPB-101
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of moderate or severe COPD exacerbation events
measured From Day 1 (Baseline) up to Week 108
Permalink · UPB's whole pipeline · Catalyst calendar · Every registered study · What changed